54 results about "Maintenance dose" patented technology

Methods for administering probiotics comprising the steps of: administering a loading dose of a loading probiotic for a loading time period; and administering a dose of a botanical and / or additional materials for the loading time period are disclosed. The methods also include administering a maintenance dose of a maintenance probiotic, and / or a botanical and / or an additional material for a maintenance time period. Also disclosed are kits for use in administering probiotics.

The invention discloses a user score-based project recommendation method. The method comprises the following steps: in allusion to the dynamism and diversity of interests of a user in a recommendation system, effectively fusing a maintenance dose function on the basis of the sores of user projects and completing the global learning of potential interests of the user by adopting a probability topic model according to the global influences, on the interests of the user, of the time factors; and in allusion to the sensitivity, for potential scenario change, of the learning process, user personalization-oriented secondary updating learning is carried out on the interests on the basis of a concept drift problem according to the local influences, on the potential interests of the user, of the time factors; and finally calculating the degrees of supporting the projects by the user through analyzing the interests of the user, and carrying out sorting to generate a project recommendation list. According to the method, the influences, caused by the recommendation performance, of the concept drift problem can be effectively avoided and the whole recommendation quality of the system can be improved under the condition of sufficiently mining the potential interests of the user.

The invention relates to a method for quickly and efficiently testing liquid absorptivity of a pole piece. The method comprises the following steps: cutting a pole piece sample, and weighing the pole piece sample to obtain the mass M0; putting the weighed pole piece sample into a container; pouring a soaking solution into the container, and immersing the pole piece sample; putting the container into a vacuum drying oven, and keeping for 15-20 minutes; taking out the pole piece, wiping the free soaking solution on the surface of the pole piece sample by using filter paper, and weighing the pole piece sample to obtain the mass M1; and calculating the liquid absorptivity epsilon=(M1-M0) / M0 and the electrolyte maintenance dose M=epsilon*M0*rho1 / rho2, wherein rho1 is the electrolyte concentration, and rho2 is the density of the soaking solution. The used octadecane has the advantages of high stability, high flash point and low volatility, is hydrophobic, and thus, is suitable to be used as a solvent for soaking the pole piece. The method overcomes the defects of long time consumption, big measurement errors, great environmental pollution caused by the electrolyte and potential hazards to the operating personnel when the electrolyte is used for soaking the pole piece and testing the liquid absorptivity in the past.

The present invention relates to methods and materials for modulating the complement alternative pathway (CAP), the complement classical pathway (CCP), the complement lectin / mannose pathway (CMP), or combinations thereof, as well as methods and materials for targeting diagnostic, prophylactic and therapeutic agents to localized areas of tissue within the body where they may more directly exert their effects upon the intended target cells or tissue, with reduced, associated systemic effects compared with administration of the same or similar agents in an untargeted, systemic manner. The methods and materials of the present invention may therefore allow for increased efficacy, lower threshold effective dosages and / or lower effective maintenance doses, and / or reduced associated undesired or adverse effects in terms of frequency or severity of occurrence, or both. The present invention also relates to methods and materials for modulating a host humoral immune response, especially reducing, inhibiting, or preventing a host humoral immune response.

The invention is related to methods and compositions for increasing milk production in animals using a saponin containing composition. In an embodiment, the invention is a method for increasing milk production of an animal comprising administering an initiation dose of a saponin-containing composition to the animal within five days before or after the time of freshening of the animal, and administering a plurality of maintenance doses of the saponin-containing composition to the animal.

Novel dosing regimens for the treatment and prevention of bacterial infections using fusidic acid are described. The use of a high loading dose of fusidic acid, followed by moderate maintenance doses of the drug, have been found to prevent development of drug-resistant strains of bacteria, to increase the effective spectrum of the drug, and to avoid nausea and vomiting associated with a prolonged course of therapy of high amounts of the drug.

The present invention relates to methods and materials for modulating the complement alternative pathway (CAP), the complement classical pathway (CCP), the complement lectin / mannose pathway (CMP), or combinations thereof, as well as methods and materials for targeting diagnostic, prophylactic and therapeutic agents to localized areas of tissue within the body where they may more directly exert their effects upon the intended target cells or tissue, with reduced, associated systemic effects compared with administration of the same or similar agents in an untargeted, systemic manner. The methods and materials of the present invention may therefore allow for increased efficacy, lower threshold effective dosages and / or lower effective maintenance doses, and / or reduced associated undesired or adverse effects in terms of frequency or severity of occurrence, or both. The present invention also relates to methods and materials for modulating a host humoral immune response, especially reducing, inhibiting, or preventing a host humoral immune response.

The invention is related to methods and compositions for increasing milk production in animals using a saponin containing composition. In an embodiment, the invention is a method for increasing milk production of an animal comprising administering an initiation dose of a saponin-containing composition to the animal within five days before or after the time of freshening of the animal, and administering a plurality of maintenance doses of the saponin-containing composition to the animal.

Disclosed are methods for the therapeutic administration of bispecific scFv conjugates as single doses at at least weekly intervals. In certain embodiments the conjugate is MM-111 and is administered at intervals of every two weeks or every three weeks. In other embodiments a single loading dose of MM-111 is administered to a human patient followed at at least weekly intervals by a least a single maintenance dose of MM-111. The loading dose is larger than the maintenance dose.

The invention relates to a method of treatment of bodies of water such as recreational pools, spas and hot tubs with maintenance doses of water treatment chemicals to achieve consistent sanitization and aesthetically pleasing levels of properties such as turbidity. The amount f the maintenance doses is based on the volume of water to be treated in order to achieve hygienic and clear water. The method can bt automated for accurate, consistent and safe treatment of water such as found in swimming pools, spas or hot tubs.

Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof. Another method includes: administering once-daily to the subject in need thereof, an oral load dose formulation having from 240 mg to 480 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof; and thereafter administering once-daily to the subject, an oral maintenance dose formulation having 80 mg to 160 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.

A method for therapeutically treating medical conditions requiring chronic therapy such as fibrocystic breast disease, endometriosis, ovarian cysts, uterine fibroids and including the treatment of women considered to be at risk to breast and / or ovarian cancer without causing an overt thyroid disease by first administering to a patient a daily loading dose of molecular iodine (I2) for a time period not to exceed six months and preferably 2 to 4 months at a concentration level sufficient to remediate symptoms associated with the medical condition followed by daily dosing with a maintenance dose of I2 after treatment of the loading dose is completed with the concentration of the maintenance dose being substantially less than the concentration of the loading dose.

A method of treatment using carvedilol is disclosed, wherein the carvedilol decreases the risk of mortality caused by congestive heart failure in patients. The patients are titrated with low amounts of carvedilol, with the initial titration dosage being only 10 to 30% of the daily maintenance dose.

The invention discloses a mathematical model for predicting voriconazole maintenance dose by integrating multiple factors and application, and relates to the technical field of medical treatment, and the model is prepared by the following steps: (1) determining the influence of CYP2C19 gene polymorphism on the use of voriconazole steady-state plasma concentration (VCZ-Cmin) by invasive fungal infection patients through variance analysis; (2) confirming the influence of CRP, PCT, IL-6 and combined use of a proton pump inhibitor on VCZ-Cmin; (3) confirming the influence of oriented use of voriconazole and non-oriented medication of different CYP2C19 genotypes on the curative effect and adverse reaction of a patient; (4) predicting risk factors influencing the VCZ-Cmin and risk factors influencing the voriconazole maintenance dosage; and (5) establishing a mathematical model for predicting the voriconazole maintenance dose and verifying the model. According to the influence factors and the mathematical prediction model disclosed by the invention, the accuracy of the sustaining dose of the clinically used voriconazole is improved, the drug concentration can be quickly stabilized in a target valley concentration range, the medication of the voriconazole is more accurate, safe and effective, and the adverse reaction is reduced.

An embodiment of the present invention comprises a method of treating malignancies in a subject in need of treatment comprising administering to the subject a high loading dose of a pegylated liposomal doxorubicin (PLD) in an initial cycle, followed by a reduced dose in a second cycle, wherein the second cycle reduced dose is in the range of 20% to 50%, preferably 50%, of the initial loading dose, and thereafter one or more maintenance doses in further cycles. The interval between dose cycles is in the range of about three-to-four weeks, preferably about four weeks. The initial loading dose is in the range of between the maximum tolerated dose (MTD) and the recommended dose, preferably the MTD (for instance, in the range of about 70 mg / m2 to 50 mg / m2, preferably 60 mg / m2). The one or more maintenance doses are in the range of about 40 mg / m2 to 50 mg / m2, preferably 45 mg / m2).

Abstract A dosage regimen for treating vascular disease in a human comprising the steps of administering a loading dosage of about 30 mg to 70 mg of loading dose of prasugrel or a pharmaceutically acceptable salt thereof, and thereafter administering a daily dosage regimen of about 7.5 mg to 15 mg maintenance dose of prasugrel or a pharmaceutically acceptable salt thereof.

A method of cancer intervention or eradication by administering an effective amount of an endogenous ligand for the aryl hydrocarbon (Ah) receptor (AhR) named ITE or one of its analogs (the active ingredient) to a subject with cancer is disclosed. An effective dose and dosing frequency of the active ingredient are determined by measuring its blood levels of the subject after dosing. The active ingredient formulated with a carrier system is applied topically, enterally, or parenterally to the subject. The formulated drug can also be administered together with one or more of other cancer therapeutic agents. A maintenance dosing is provided after the subject is free of cancer to insure the cancer eradication. Subjects with cancers of prostate, liver, lung, ovarian, and breast are preferably accepted for treatment.